BAKER BROS ADVISORS LP's Q3 2024 13F: 5 new positions, 6 exits

Form 13F-HR for the quarter ended Sep 30, 2024 · filed Nov 14, 2024 · 92 reported positions · accession 0001104659-24-118899

View the filing on SEC.gov

What changed this quarter

Activity Security Weight before Weight now Change Shares Shares %
Increased Insmed Incorporated (INSM) 3.1% 3.4% +0.3 pts +840K sh +23%
Increased CRISPR Therapeutics AG (CRSP) 0.1% 0.4% +0.3 pts +743K sh +743%
Exited Cerevel Therapeutics Holdings, Inc. (CERE) 0.4% — −0.4 pts −684K sh −100%
Increased Summit Therapeutics Inc. (SMMT) 2.4% 5.6% +3.2 pts +1.2M sh +5%
Increased Immunovant, Inc. (IMVT) 0.2% 0.4% +0.2 pts +761K sh +164%
New Bicara Therapeutics Inc. (BCAX) — 0.2% +0.2 pts +833K sh new
Increased Praxis Precision Medicines, Inc. (PRAX) 0.1% 0.2% +0.1 pts +192K sh +146%
Increased Replimune Group, Inc. (REPL) 1.2% 1.3% +0.1 pts +1M sh +10%
Increased Centessa Pharmaceuticals plc (CNTA) 0.1% 0.2% +0.1 pts +678K sh +123%
Exited Athira Pharma, Inc. (ATHA) 0.1% — −0.1 pts −3.15M sh −100%
New Arvinas, Inc. (ARVN) — 0.1% +0.1 pts +406K sh new
New Ionis Pharmaceuticals, Inc. (IONS) — 0.1% +0.1 pts +223K sh new
Increased Ultragenyx Pharmaceutical Inc. (RARE) 0.8% 0.9% +0.1 pts +110K sh +7%
Exited Talis Biomedical Corporation (TLIS) 0.1% — −0.1 pts −508K sh −100%
New Structure Therapeutics Inc. (GPCR) — 0.0% 0.0 pts +85,500 sh new
Increased Skye Bioscience, Inc. (SKYE) 0.1% 0.1% 0.0 pts +935K sh +187%
Exited Adaptimmune Therapeutics plc (ADAPY) 0.0% — 0.0 pts −2.34M sh −100%
New Wave Life Sciences Ltd. (WVE) — 0.0% 0.0 pts +344K sh new
Increased Xencor, Inc. (XNCR) 0.1% 0.1% 0.0 pts +125K sh +23%
Exited Sage Therapeutics, Inc. (SAGE) 0.0% — 0.0 pts −171K sh −100%
Increased Generation Bio Co. (GBIO) 0.0% 0.1% 0.0 pts +738K sh +61%
Exited Achilles Therapeutics plc (ACHL) 0.0% — 0.0 pts −1.11M sh −100%
Increased Design Therapeutics, Inc. (DSGN) 0.1% 0.1% 0.0 pts +48,431 sh +3%
Increased IGM Biosciences, Inc. (IGMS) 0.4% 0.7% +0.3 pts +1,994 sh 0%
Increased Incyte Corporation (INCY) 24.3% 21.3% −3.0 pts +496 sh 0%
Reduced NewAmsterdam Pharma Company N.V. (NAMS) 0.0% 0.0% 0.0 pts −116 sh 0%
Increased Rhythm Pharmaceuticals, Inc. (RYTM) 3.4% 3.5% +0.1 pts +1 sh 0%
Increased Kymera Therapeutics, Inc. (KYMR) 2.3% 3.0% +0.6 pts +1 sh 0%
Reduced HOOKIPA Pharma Inc. (HOOK) 0.1% 0.0% 0.0 pts −1 sh 0%

Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled

† Security identifier (CUSIP) changed — read as one continuing position, not an exit and a new position:

  • Aligos Therapeutics, Inc. (ALGS): 01626L105 → 01626L204, 2.08M → 83,055 shares (share count change consistent with a stock split)

Top 10 positions — 78.7% of the equity book

No changes in the top 10 this quarter

# Security Weight before Weight now
1 BeiGene, Ltd. (ONC) 19.6% 24.8%
2 Incyte Corporation (INCY) 24.3% 21.3%
3 ACADIA Pharmaceuticals Inc. (ACAD) 9.1% 6.9%
4 Summit Therapeutics Inc. (SMMT) 2.4% 5.6%
5 Madrigal Pharmaceuticals, Inc. (MDGL) 7.2% 4.4%
6 Revolution Medicines, Inc. (RVMD) 3.8% 3.6%
7 Rhythm Pharmaceuticals, Inc. (RYTM) 3.4% 3.5%
8 Insmed Incorporated (INSM) 3.1% 3.4%
9 Kymera Therapeutics, Inc. (KYMR) 2.3% 3.0%
10 Bicycle Therapeutics plc (BCYC) 2.5% 2.2%

Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).